See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Analysis of post COVID-19 condition after ensitrelvir treatment in asymptomatic or mild-symptoms only patients in the SCORPIO phase2b/3 Study
Analysis of post COVID-19 condition after ensitrelvir treatment in asymptomatic or mild-symptoms only patients in the SCORPIO phase2b/3 Study
Antimicrobial activity of cefiderocol and comparator agents against isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia by infection type from United States hospitals in the SENTRY Antimicrobial Surveillance Program (2020-2022)
Antimicrobial activity of cefiderocol and comparator agents against isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia by infection type from United States hospitals in the SENTRY Antimicrobial Surveillance Program (2020-2022)
Cefiderocol activity against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized cinical isolates, causing infections in United States hospitals (2020–2023)
Cefiderocol activity against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized cinical isolates, causing infections in United States hospitals (2020–2023)
Cefiderocol activity against clinical Enterobacterales isolates carrying metallo-β-lactamase genes in United States and European Hospitals (2020–2023)
Cefiderocol activity against clinical Enterobacterales isolates carrying metallo-β-lactamase genes in United States and European Hospitals (2020–2023)
Cefiderocol activity against Pseudomonas aeruginosa clinical isolates carrying metallo-β-lactamase genes in United States and European Hospitals (2020–2023)
Cefiderocol activity against Pseudomonas aeruginosa clinical isolates carrying metallo-β-lactamase genes in United States and European Hospitals (2020–2023)
Cefiderocol activity against Pseudomonas aeruginosa, including resistant subsets and isolates carrying carbapenemase β-lactamase genes, from United States hospitals (2020–2023)
Cefiderocol activity against Pseudomonas aeruginosa, including resistant subsets and isolates carrying carbapenemase β-lactamase genes, from United States hospitals (2020–2023)
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
